CONTEXT THERAPEUTICS INC. Stock-Based Compensation
CONTEXT THERAPEUTICS INC. (CNTX) reported Stock-Based Compensation of $937.32 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- CONTEXT THERAPEUTICS INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $528.10K, a 35.72% increase year-over-year.
- CONTEXT THERAPEUTICS INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $409.22K, a 39.32% increase year-over-year.
- CONTEXT THERAPEUTICS INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $325.17K, a 40.27% increase year-over-year.
- CONTEXT THERAPEUTICS INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $323.08K, a 51.68% increase year-over-year.
- CONTEXT THERAPEUTICS INC. share-based payment arrangement, noncash expense for fiscal 2025 was $1.33M, a 58.11% increase from fiscal 2024.
- CONTEXT THERAPEUTICS INC. share-based payment arrangement, noncash expense for fiscal 2024 was $841.87K, a 21.82% decline from fiscal 2023.
- CONTEXT THERAPEUTICS INC. share-based payment arrangement, noncash expense for fiscal 2023 was $1.08M, a 10.28% increase from fiscal 2022.
- CONTEXT THERAPEUTICS INC. share-based payment arrangement, noncash expense for fiscal 2022 was $976.44K, a 91.05% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $528.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $937.32K 10-Q · filed 2026-08-05 | $1.26M derived: sum of 3 quarters · filed 2026-08-05 | $1.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $409.22K 10-Q · filed 2026-05-06 | $734.39K derived: sum of 2 quarters · filed 2026-05-06 | $1.06M derived: sum of 3 quarters · filed 2026-05-06 | $1.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $325.17K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $648.25K derived: sum of 2 quarters · filed 2026-03-23 | $1.04M derived: sum of 3 quarters · filed 2026-08-05 | $1.33M 10-K · filed 2026-03-23 |
| 2025-09-30 | $323.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $712.20K derived: sum of 2 quarters · filed 2026-08-05 | $1.01M 10-Q · filed 2025-11-05 | $1.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $389.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $682.83K 10-Q · filed 2026-08-05 | $914.65K derived: sum of 3 quarters · filed 2026-08-05 | $1.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $293.72K 10-Q · filed 2026-05-06 | $525.54K derived: sum of 2 quarters · filed 2026-05-06 | $738.54K derived: sum of 3 quarters · filed 2026-05-06 | $895.58K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $231.82K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $444.82K derived: sum of 2 quarters · filed 2026-03-23 | $601.86K derived: sum of 3 quarters · filed 2026-03-23 | $841.87K 10-K · filed 2026-03-23 |
| 2024-09-30 | $213.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $370.04K derived: sum of 2 quarters · filed 2025-11-05 | $610.05K 10-Q · filed 2025-11-05 | $866.10K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $157.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $397.04K 10-Q · filed 2025-08-06 | $653.10K derived: sum of 3 quarters · filed 2025-08-06 | $908.04K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $240.01K 10-Q · filed 2025-05-07 | $496.06K derived: sum of 2 quarters · filed 2025-05-07 | $751.01K derived: sum of 3 quarters · filed 2025-05-07 | $1.03M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $256.05K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $511.00K derived: sum of 2 quarters · filed 2025-03-20 | $794.10K derived: sum of 3 quarters · filed 2025-03-20 | $1.08M 10-K · filed 2025-03-20 |
| 2023-09-30 | $254.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $538.05K derived: sum of 2 quarters · filed 2024-11-06 | $820.81K 10-Q · filed 2024-11-06 | $1.06M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $283.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $565.87K 10-Q · filed 2024-08-07 | $809.50K derived: sum of 3 quarters · filed 2024-08-07 | $1.09M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $282.76K 10-Q · filed 2024-05-08 | $526.40K derived: sum of 2 quarters · filed 2024-05-08 | $802.92K derived: sum of 3 quarters · filed 2024-05-08 | $1.04M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $243.64K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $520.16K derived: sum of 2 quarters · filed 2024-03-21 | $761.48K derived: sum of 3 quarters · filed 2024-03-21 | $976.44K 10-K · filed 2024-03-21 |
| 2022-09-30 | $276.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $517.85K derived: sum of 2 quarters · filed 2023-11-09 | $732.80K 10-Q · filed 2023-11-09 | $937.18K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $241.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $456.28K 10-Q · filed 2023-08-09 | $660.66K derived: sum of 3 quarters · filed 2023-08-09 | $822.49K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $214.96K 10-Q · filed 2023-05-10 | $419.34K derived: sum of 2 quarters · filed 2023-05-10 | $581.16K derived: sum of 3 quarters · filed 2023-05-10 | $700.52K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $204.38K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $366.20K derived: sum of 2 quarters · filed 2023-03-22 | $485.57K derived: sum of 3 quarters · filed 2023-03-22 | $511.08K 10-K · filed 2023-03-22 |
| 2021-09-30 | $161.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $281.19K derived: sum of 2 quarters · filed 2022-11-09 | $306.70K 10-Q · filed 2022-11-09 | $337.52K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $119.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $144.88K 10-Q · filed 2022-08-11 | $175.69K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $25.51K 10-Q · filed 2022-05-11 | $56.33K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $30.82K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $219.25K 10-K · filed 2022-03-23 | ||
| 2020-09-30 | $188.43K 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |